📊 CADL Key Takeaways
Is Candel Therapeutics, Inc. (CADL) a Good Investment?
Candel Therapeutics is a pre-revenue clinical-stage biopharmaceutical company burning significant cash with minimal commercial traction ($102K revenue) and negative operating margins exceeding -47,000%. Despite adequate liquidity buffers, the company's path to profitability remains highly uncertain with ongoing substantial losses and deteriorating cash position.
Candel Therapeutics shows very weak operating fundamentals, with essentially no revenue base against large and recurring losses, deeply negative margins, and substantial cash burn. The balance sheet is supported by a large cash position and strong near-term liquidity, but growth quality is poor and the business remains dependent on external capital or future clinical/commercial milestones to improve sustainability.
Why Buy Candel Therapeutics, Inc. Stock? CADL Key Strengths
- Strong cash position of $119.7M provides 2-3 years of runway at current burn rate
- Excellent liquidity ratios (13.49x current ratio) ensure near-term solvency
- Manageable debt load relative to equity (0.89x D/E ratio) limits leverage risk
- Very strong short-term liquidity with $119.73M in cash and a 13.49x current ratio
- Moderate balance sheet support from $51.92M in equity relative to total assets of $125.19M
- Net loss per share improved year over year, indicating some reduction in per-share loss pressure
CADL Stock Risks: Candel Therapeutics, Inc. Investment Risks
- Severe unprofitability with -$38.2M net loss on near-zero revenue indicates business model execution failure
- Negative free cash flow of -$38.9M annually suggests unsustainable cash burn without milestone achievements
- Pre-commercial stage with minimal revenue generation indicates clinical development challenges and delayed commercialization timeline
- EPS of -$0.72 and negative ROE/ROA confirm value destruction for shareholders
- Revenue remains negligible at $102.00K, showing no meaningful commercial scale or operating traction
- Heavy operating and free cash flow losses suggest the business is not self-funding and may require future financing
- Leverage is meaningful for a loss-making company, with $46.12M in long-term debt and negative interest coverage
Key Metrics to Watch
- Revenue growth trajectory and evidence of clinical trial advancement
- Monthly cash burn rate relative to cash reserves remaining
- Clinical development milestones and regulatory approval progress
- Operating cash flow improvements toward breakeven
- Quarterly operating cash burn and cash runway
- Revenue growth and progress toward narrowing operating losses
Candel Therapeutics, Inc. (CADL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 13.49x current ratio provides a solid financial cushion.
CADL Profit Margin, ROE & Profitability Analysis
CADL vs Healthcare Sector: How Candel Therapeutics, Inc. Compares
How Candel Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Candel Therapeutics, Inc. Stock Overvalued? CADL Valuation Analysis 2026
Based on fundamental analysis, Candel Therapeutics, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Candel Therapeutics, Inc. Balance Sheet: CADL Debt, Cash & Liquidity
CADL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Candel Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.74 indicates the company is currently unprofitable.
CADL Revenue Growth, EPS Growth & YoY Performance
CADL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $31.0K | -$8.4M | $-0.29 |
| Q2 2023 | $31.0K | -$4.1M | $-0.14 |
| Q1 2023 | $31.0K | -$874.0K | $-0.03 |
| Q3 2022 | $31.0K | -$8.7M | $-0.30 |
| Q2 2022 | $31.0K | -$4.1M | $-0.14 |
| Q1 2022 | $31.0K | -$874.0K | N/A |
| Q3 2021 | $31.0K | -$2.6M | N/A |
| Q2 2021 | $31.0K | -$2.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Candel Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
CADL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Candel Therapeutics, Inc. (CIK: 0001841387)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CADL
What is the AI rating for CADL?
Candel Therapeutics, Inc. (CADL) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CADL's key strengths?
Claude: Strong cash position of $119.7M provides 2-3 years of runway at current burn rate. Excellent liquidity ratios (13.49x current ratio) ensure near-term solvency. ChatGPT: Very strong short-term liquidity with $119.73M in cash and a 13.49x current ratio. Moderate balance sheet support from $51.92M in equity relative to total assets of $125.19M.
What are the risks of investing in CADL?
Claude: Severe unprofitability with -$38.2M net loss on near-zero revenue indicates business model execution failure. Negative free cash flow of -$38.9M annually suggests unsustainable cash burn without milestone achievements. ChatGPT: Revenue remains negligible at $102.00K, showing no meaningful commercial scale or operating traction. Heavy operating and free cash flow losses suggest the business is not self-funding and may require future financing.
What is CADL's revenue and growth?
Candel Therapeutics, Inc. reported revenue of $102.0K.
Does CADL pay dividends?
Candel Therapeutics, Inc. does not currently pay dividends.
Where can I find CADL SEC filings?
Official SEC filings for Candel Therapeutics, Inc. (CIK: 0001841387) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CADL's EPS?
Candel Therapeutics, Inc. has a diluted EPS of $-0.72.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CADL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Candel Therapeutics, Inc. has a SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CADL stock overvalued or undervalued?
Valuation metrics for CADL: ROE of -73.5% (sector avg: 15%), net margin of -37,433.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CADL stock in 2026?
Our dual AI analysis gives Candel Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CADL's free cash flow?
Candel Therapeutics, Inc.'s operating cash flow is $-38.3M, with capital expenditures of $587.0K. FCF margin is -38,135.3%.
How does CADL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -37,433.3% (avg: 12%), ROE -73.5% (avg: 15%), current ratio 13.49 (avg: 2).